Обоснование коротких курсов антибактериальной терапии
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Список литературы
1. Инфекционная заболеваемость в Российской Федерации за январь–декабрь 2006 г. Дет. инф. 2007; 6 (1): 3.
2. Esposito S et al. Mycoplasma pnеumoniae and Chlamydiae pneumoniae as aetiological agents of recurent respiratory tract infections. ICMAS-Ko. 2000.
3. Таточенко В.К., Катосова Л.К. Антибиотики при бактериальных ОРЗ у детей. Антибиот. и химиотер. 1999; 9: 13–8.
4. Таточенко В.К. и др. О тактике антибактериальной терапии острых респираторных заболеваний у детей на поликлиническом участке. Вопр. совр. педиатр. 2002; 1 (5): 11–4.
5. Nuguist AS, Gonsales R, Steiner JF, Sande MA. Назначение антибиотиков детям при простудных заболеваниях, респираторных инфекциях и бронхите. Рос. вестн. перинатол. и педиатр. 1998; 6: 48–9.
6. Чемоданов В.В. Новая эра – новые стандарты назначения антибиотиков. Практика педиатра. 2004; 12: 18–21.
7. Retsema JA. Susceptibility and resistance emergence studies with macrolides. In J Antimicrob Agents 1999; 11 (Suppl.): 15–21.
8. Bryskier A, Agouridans C, Chantot J-F. Macrolides, azalides and streptogramines: structure and activity. In: Neu HC, Young LS, Zinner SH, eds. The New Macrolides, Azalides and Streptogramins. Pharmacology and Clinical Applications. New York: Marcel Dekker, 1993; р. 3–11.
9. Yanagihara K, Izumikawa K, Higa F et al. Efficacy of Azithromycin in the Treatment of Community-acquired Pneumonia, Including Patients with Macrolide-Resistant Streptococcus pneumoniae. Infection Inter Med 2009; 48: 527–35.
10. Karlström A, Boyd K, English K et al. Treatment with Protein Synthesis Inhibitors Improves Outcomes of Secondary Bacterial Pneumonia after Influenza. J Infect Dis 2009; 199: 1–9.
11. Labro MT, El Benna J, Babin-Chevaye C. Comparison of the vitro effect of several macrolides on the oxidative burst of human neutrophils. J Antimicrob Chemother 1989; 24: 561–72.
12. Takeoka K, Ichimiya T, Yamasaki T. The in vitro effect of macrolides on the interaction of human polymorphonuclear leukocytes with Pseudomonas aeruginosa in biofilm. Chemotherapy 1998; 44: 190–7.
13. Nachata MC et al. Pharmacokinetics of azithromycin in pediatric patients after oral administration of multiple doses of suspension. Antimicrob Agents Chemother 1993; 37: 314–6.
14. Pucander J. Penetration of azithromycin into middle ear effusions in acute and secretory otitis media in children. J Antimicrob Chemother 1996; Suppl. C: 53–61.
15. Cohen R et al. Comparison of two dosages of azithromycin for three days versus penicillin V for ten days in acute group A streptococcal tonsillopharyngitis. Pediatr Infect Dis J 2002; 21: 297–303.
16. Scaglione F et al. Interpretation of middle ear fluid concentrations of antibiotics: comparison between ceftibufen, cefixime and azithromycin. Br J Clin Pharmacol 1999; 47 (3): 267–71.
17. FDA Briefing Package: Zithromax (Azithromycin) Oral Suspension Singl-Dose and Three-Day Treatment of Acute Otitis Media. Anti-Infective Avisory Commitee 2001; Novemder 7.
18. Cuzzolin L, Fanos V. Use of Macrolids in children: A Review of the Literature. Inf Med 2002; 19 (6): 279–85.
19. Hopkins S. Clinical safety and tolerance of azithromycin in children. J Antimicrob Chemother 1993; 31 (Suppl. E): 111–7.
2. Esposito S et al. Mycoplasma pnеumoniae and Chlamydiae pneumoniae as aetiological agents of recurent respiratory tract infections. ICMAS-Ko. 2000.
3. Таточенко В.К., Катосова Л.К. Антибиотики при бактериальных ОРЗ у детей. Антибиот. и химиотер. 1999; 9: 13–8.
4. Таточенко В.К. и др. О тактике антибактериальной терапии острых респираторных заболеваний у детей на поликлиническом участке. Вопр. совр. педиатр. 2002; 1 (5): 11–4.
5. Nuguist AS, Gonsales R, Steiner JF, Sande MA. Назначение антибиотиков детям при простудных заболеваниях, респираторных инфекциях и бронхите. Рос. вестн. перинатол. и педиатр. 1998; 6: 48–9.
6. Чемоданов В.В. Новая эра – новые стандарты назначения антибиотиков. Практика педиатра. 2004; 12: 18–21.
7. Retsema JA. Susceptibility and resistance emergence studies with macrolides. In J Antimicrob Agents 1999; 11 (Suppl.): 15–21.
8. Bryskier A, Agouridans C, Chantot J-F. Macrolides, azalides and streptogramines: structure and activity. In: Neu HC, Young LS, Zinner SH, eds. The New Macrolides, Azalides and Streptogramins. Pharmacology and Clinical Applications. New York: Marcel Dekker, 1993; р. 3–11.
9. Yanagihara K, Izumikawa K, Higa F et al. Efficacy of Azithromycin in the Treatment of Community-acquired Pneumonia, Including Patients with Macrolide-Resistant Streptococcus pneumoniae. Infection Inter Med 2009; 48: 527–35.
10. Karlström A, Boyd K, English K et al. Treatment with Protein Synthesis Inhibitors Improves Outcomes of Secondary Bacterial Pneumonia after Influenza. J Infect Dis 2009; 199: 1–9.
11. Labro MT, El Benna J, Babin-Chevaye C. Comparison of the vitro effect of several macrolides on the oxidative burst of human neutrophils. J Antimicrob Chemother 1989; 24: 561–72.
12. Takeoka K, Ichimiya T, Yamasaki T. The in vitro effect of macrolides on the interaction of human polymorphonuclear leukocytes with Pseudomonas aeruginosa in biofilm. Chemotherapy 1998; 44: 190–7.
13. Nachata MC et al. Pharmacokinetics of azithromycin in pediatric patients after oral administration of multiple doses of suspension. Antimicrob Agents Chemother 1993; 37: 314–6.
14. Pucander J. Penetration of azithromycin into middle ear effusions in acute and secretory otitis media in children. J Antimicrob Chemother 1996; Suppl. C: 53–61.
15. Cohen R et al. Comparison of two dosages of azithromycin for three days versus penicillin V for ten days in acute group A streptococcal tonsillopharyngitis. Pediatr Infect Dis J 2002; 21: 297–303.
16. Scaglione F et al. Interpretation of middle ear fluid concentrations of antibiotics: comparison between ceftibufen, cefixime and azithromycin. Br J Clin Pharmacol 1999; 47 (3): 267–71.
17. FDA Briefing Package: Zithromax (Azithromycin) Oral Suspension Singl-Dose and Three-Day Treatment of Acute Otitis Media. Anti-Infective Avisory Commitee 2001; Novemder 7.
18. Cuzzolin L, Fanos V. Use of Macrolids in children: A Review of the Literature. Inf Med 2002; 19 (6): 279–85.
19. Hopkins S. Clinical safety and tolerance of azithromycin in children. J Antimicrob Chemother 1993; 31 (Suppl. E): 111–7.
Авторы
Ф.С.Харламова
ГОУ ВПО Российский государственный медицинский университет, Москва
ГОУ ВПО Российский государственный медицинский университет, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.